Ayman Elkadry, MD
Endocrinology, Diabetes & Metabolism · Huntington, WVNPI 1861606808
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,253 of the $13,330 with a category attached, or 84.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,655, 3.3 times the $1,110 reported in 2019.
Across 540 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$2K
- Lilly USA, LLC$1K
- Amgen$1K
- Senseonics, Incorporated$792
- Medtronic$625
- plus $6K from 54 others
Across 64 payments — averaging $11,780 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Operations, Inc.$485K
- AbbVie$269K
What the payments were for
- Consulting fees$1,57512%
- Speaking & faculty fees$4003%
- Travel & lodging$120%
- Food & beverage$11,25384%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,330 in reported general payments places this provider in the 85th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,162 | $1,228,098 |
| TrulicityDulaglutide | 904 | $964,564 |
| JardianceEmpagliflozin | 1,099 | $761,358 |
| MounjaroTirzepatide | 480 | $532,861 |
| TepezzaTeprotumumab-Trbw | 11 | $516,792 |
| FarxigaDapagliflozin Propanediol | 604 | $415,318 |
| JanuviaSitagliptin Phosphate | 398 | $255,235 |
| GenotropinSomatropin | 91 | $204,163 |
| TradjentaLinagliptin | 193 | $115,130 |
| Norditropin FlexproSomatropin | 40 | $105,866 |
| JanumetSitagliptin Phos/Metformin Hcl | 154 | $103,373 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 209 | $89,488 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 568 | $75,062 |
| Tresiba Flextouch U-100Insulin Degludec | 145 | $69,404 |
| OmnitropeSomatropin | 26 | $65,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,244 | $1,497,4251,384 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus, Novolog, Fiasp | $2,154 | $1,385,9221,371 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Trijardy Xr | $126 | $944,8351,387 claims |
| AmgenTepezza, Prolia | $1,145 | $555,65434 claims |
| AstraZenecaFarxiga | $256 | $415,318604 claims |
| MerckJanuvia, Janumet | $75 | $358,608552 claims |
| PfizerGenotropin | $118 | $204,16391 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Huntington
- Daniel MaciasHuntington$686K
- Henry DriscollHuntington$1K
- Mateen HotianaHuntington$1K
- John LeidyHuntington$864
- Ronald InnerfieldHuntington$833
- Sobia FaisalHuntington$705
- Henin AlsamarraieHuntington$695
- Nesreen BenhamedHuntington$526
- Maria Luzuriaga BassanteHuntington$421
- Muhammad HaqHuntington$280
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.